CorMedix (CRMD) Reports In-Line Q2 EPS

CorMedix (NASDAQ: CRMD) reported Q2 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $810 thousand versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
• Nebius releases AI Cloud 3.6 with new agent and security tools
• Lockheed Martin unveils next-generation hypersonic glide body